921MO Phase I global study of Iza-Bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and other solid tumors
Year: 2025
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Authors: H.A. Yu, X. Le, M.L. Johnson, N. Iannotti, A.I. Spira, P.A. Jänne, M. Furqan, T. Patil, G. Lopes, C.A. Perez, W.J. Edenfield, S.V. Liu, Z. Piotrowska, C. Park, J.L. Zhao, H. Wang, G. Russo, H. Zhu, J. Cheng, J. Peguero
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Virginia Cancer Specialists, Dana-Farber Cancer Institute, University of Iowa Hospitals and Clinics, University of Colorado Cancer Center, University of Colorado Anschutz, Sylvester Comprehensive Cancer Center, Florida Cancer Specialists & Research Institute, Prisma Health, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Massachusetts General Hospital, University of California, Irvine, University of California, Irvine Medical Center, UC Irvine Health, AstraZeneca (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415942500